RINVOQ® is an oral selective and reversible JAK inhibitor indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.1
Find out how RINVOQ’s flexible dosing regimen can support your patients – explore the resources below.
The recommended dose of RINVOQ is 15 mg or 30 mg once daily based on individual patient presentation.
– A dose of 30 mg once daily may be appropriate for patients with high disease burden
– A dose of 30 mg once daily may be appropriate for patients with an inadequate response to 15 mg once daily
– The lowest effective dose for maintenance should be considered
For patients ≥65 years of age, the recommended dose is 15 mg once daily.
For adolescents (from 12 to 17 years of age), the recommended dose is 15 mg once daily for adolescents weighing at least 30 kg.*
Consideration should be given to discontinuing RINVOQ treatment in any patient who shows no evidence of therapeutic benefit after 12 weeks of treatment.
RINVOQ INITIATION GUIDE
Start your patients on RINVOQ with this practical guide for dosing, initiation, and monitoring.
WHICH PATIENTS MIGHT BENEFIT FROM RINVOQ?
Dr Melinda Gooderham, Medical Director at the SKiN Centre for Dermatology and the Principal Investigator for the SKiN Research Centre in Ontario, Canada, shares her thoughts on which patients may benefit from RINVOQ.
INITIATING AND MANAGING PATIENTS ON RINVOQ
Dr Melinda Gooderham, Medical Director at the SKiN Centre for Dermatology and the Principal Investigator for the SKiN Research Centre in Ontario, Canada, describes her first-hand experience of initiating and managing patients on RINVOQ.
*The safety and efficacy of RINVOQ in children with moderate to severe atopic dermatitis below the age of 12 years have not been established. No data are available. No clinical exposure data are available in adolescents <40 kg. The posology in adolescent patients 30 kg to <40 kg was determined using population pharmacokinetic modeling and simulation.1
FIND OUT MORE ABOUT RINVOQ
REFERENCES
- RINVOQ® (upadacitinib) Summary of Product Characteristics. AbbVie Deutschland GmbH & Co. KG: June 2022.